Transitioning from Weekly Injections to Daily Oral Weight Management: What the New MHRA Guidelines Advise
This article discusses medicines which are legally classified as Prescription-Only Medicines (POMs). Aster operates in line with UK law, guidance and regulations, offering POMs only after a clinical consultation which results in a prescription. All information in this article is educational: If you are considering switching your treatment you must follow the directions from your prescriber.
The Medicines and Healthcare products Regulatory Agency (MHRA) has last month officially licensed the UK’s first once-daily GLP-1 receptor agonist tablet for weight loss. This medication contains semaglutide, which mimics a natural hormone to curb appetite and slow digestion, offering a needle-free alternative for the estimated 1.6 million UK adults utilising weight management medications.
However, moving from a weekly injection to a daily pill is not just a change in formatting. It requires a precise transition protocol and strict adherence to a new daily routine to ensure the medication remains effective. Put simply, you can’t just inject your last dose and start the tablets straight away.
The Official Switch Protocol
For patients currently using a weekly injection who wish to transition to the newly approved daily tablet, the clinical guidelines outline a direct, step-by-step timeline, but only for patients on a specific dosage.
If you are currently maintained on the maximum therapeutic dose of the weekly injection (2.4 mg), the regulations permit a direct switch to the maximum daily tablet dose (25 mg) without needing to restart the months-long baseline build-up process. The process would typically look like this:
Take your final injection: Day 1.
Administer your final weekly injection exactly as scheduled.
Observe the 7-day clearance window: Days 2 to 7.
Allow the weekly dose to naturally taper down in your system over the next 7 days. Do not take any oral doses during this week.
Initiate the daily tablet: Day 8.
Take your first daily tablet on the exact day your next injection would have been due. Moving forward, the medication must be taken every single morning.
We need to point out that this switch must be clinically monitored by a professional. You should not be left to work out dosing on your own.
Why the Daily Routine for Tablets is Non-Negotiable
The primary challenge of an oral weight-loss pill is getting the medication absorbed by the body. The active ingredient is a peptide (a string of amino acids) that the stomach would normally digest and destroy like standard food.
To prevent this, the tablet is co-formulated with an absorption enhancer called SNAC. This compound creates a localised zone of higher pH around the tablet, shielding it from stomach acid long enough to pass into the bloodstream. Because this process is highly sensitive, patients must follow a rigid morning routine:
Take on a Completely Empty Stomach: The tablet must be taken the moment you wake up. Any residual food in the stomach can block the drug's absorption.
Use Minimal Water: Swallow the tablet whole with a maximum of 120 ml (about half a glass) of plain water.
The 30-Minute Fast: You should wait at least 30 minutes before eating food, drinking coffee, tea, or juice, or taking any other oral medications. Consuming anything too early could render the dose ineffective.
Efficacy: How the Pill Compares to the Needle
Data from primary clinical trials demonstrates that the daily oral tablet successfully matches the weight-loss power of the weekly injection:
The Injection Baseline: Long-term clinical trials show that adults using the standard weekly injection lose an average of 15% of their total body weight over a 68-week period.
The Daily Tablet Performance: In the Phase 3 trial evaluating the mid-to-high dose tablet, participants achieved an average weight loss of 13.6% over 64 weeks, proving that the daily oral framework can deliver highly equivalent results without the need for needles.
Important Safety Updates and Side Effects
The most common side effects when transitioning to the oral tablet are gastrointestinal, including nausea, bloating, and constipation. However, regulators have highlighted severe, rare risks that apply equally to both the oral and injectable forms:
Regulatory Safety Warnings
Acute Pancreatitis: Health authorities have issued strengthened warnings regarding the risk of acute pancreatitis (inflammation of the pancreas), including rare necrotising and fatal cases. Patients must stop treatment immediately and seek urgent medical attention if they experience severe, persistent abdominal pain that radiates to the back.
Vision Risks (NAION): A dedicated drug safety update notes a very rare link to Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), a condition causing sudden, painless vision loss in one eye. Any sudden changes in eyesight require immediate clinical assessment.
UK Cost and Availability
While the tablet has officially won safety approval from the MHRA, its current availability reflects standard UK healthcare rollouts:
Private Prescriptions: The oral treatment is available immediately via private clinics and registered online pharmacies for patients meeting the eligibility criteria (a BMI of 30 kg/m² or above, or 27 kg/m² with a weight-related health condition like high blood pressure).
NHS Restrictions: The tablet is not yet available on the NHS. Under baseline clinical guidance, it must first undergo a formal cost-effectiveness appraisal to define how and when it can be utilised within public weight-management services.
Sources
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
https://pubmed.ncbi.nlm.nih.gov/37385278/
Once-Weekly Semaglutide in Adults with Overweight or Obesity
https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
https://pmc.ncbi.nlm.nih.gov/articles/PMC9515042/
1.6 million UK adults used weight loss drugs in past year
https://www.ucl.ac.uk/news/2026/jan/16-million-uk-adults-used-weight-loss-drugs-past-year
NICE Guidance: Semaglutide for managing overweight and obesity
https://www.nice.org.uk/guidance/ta875
First GLP-1 tablet for weight loss approved in the UK
https://www.gov.uk/government/news/first-glp-1-tablet-for-weight-loss-approved-in-the-uk
Wegovy 1.5 mg tablets Summary of Product Characteristics
https://www.medicines.org.uk/emc/product/102344/smpc
GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases
https://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-and-dual-glp-1-slash-gip-receptor-agonists-strengthened-warnings-on-acute-pancreatitis-including-necrotising-and-fatal-cases
Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
https://www.gov.uk/drug-safety-update/semaglutide-wegovy-ozempic-and-rybelsus-risk-of-non-arteritic-anterior-ischemic-optic-neuropathy-naion
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
https://www.nejm.org/doi/full/10.1056/NEJMoa2500969
This article was written by
Sally Proudman
Operations Manager
